Stockreport

AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting

AEON Biopharma, Inc. Class A  (AEON) 
PDF – Company is aligned with the FDA on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulin [Read more]